Quantcast

Latest Brain tumor Stories

2014-09-26 12:24:44

ASHEVILLE, N.C., Sept. 26, 2014 /PRNewswire-USNewswire/ -- The Pediatric Brain Tumor Foundation's Starry Night 8.5K is an evening walk/run to help kids battling one of the deadliest forms of childhood cancer. Starry Night Boston is coming to Joe Moakley Park on Saturday, Oct. 18. More than 28,000 children in the United States are living with a brain tumor. Each of the 28,000 steps in Starry Night's 8.5K walk/run will shine light on their illness and raise funds for lifesaving...

2014-09-25 08:26:59

Analyses of PRiDe, a registry of 457 recurrent glioblastoma patients, show that patients treated with the NovoTTF(TM)-100A System at their first and second recurrences had median overall survivals of 20.0 and 8.5 months, respectively ST. HELIER, Jersey, Sept. 25, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that survival and efficacy data from its U.S. patient registry will be presented at the European Society for Medical Oncology (ESMO) Meeting...

2014-09-23 08:30:25

Medical journey of Arizona boy precedes that of Britain's Ashya King SAN DIEGO, Sept. 23, 2014 /PRNewswire/ -- While proton therapy recently began in the Czech Republic for British pediatric brain cancer patent Ashya King, another case in the United States draws to a close today with a promising outlook, as a young boy who was given just days to live now looks forward to his first day of kindergarten. http://photos.prnewswire.com/prnvar/20140922/147644 When 5-year-old Logan Green...

2014-09-23 08:28:25

LOS ANGELES, Sept. 23, 2014 /PRNewswire/ -- On Saturday, September 27 beginning at 6:30 PM at UCLA's Schoenberg Hall and Plaza, 445 Charles E. Young Drive, East, Los Angeles, CA 90024, Art of the Brain, (AOB) an unprecedented organization of "Brain Buddies," brain cancer patients and families who celebrate art, creativity and life undefeated by brain cancer, will enjoy its 15(th) Anniversary Gala. Art of the Brain will debut the first ever art show created by brain cancer patients, in...

2014-09-22 08:28:11

Presentations include first Phase 2 results evaluating investigational compound Veliparib in patients with non-small cell lung cancer NORTH CHICAGO, Ill., Sept. 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from several clinical studies evaluating potential new medicines in the company's oncology pipeline will be presented at the upcoming 2014 European Society of Medical Oncology (ESMO) Annual Congress, September 26-30, in Madrid, Spain. Data being presented include results...

2014-09-18 23:05:34

Research conducted by a team of neurosurgeons and radiation oncologists from Allegheny Health Network, and presented this week at the American Society for Radiation Oncology annual meeting, has documented improved survival in patients with cancerous brain tumors who undergo both surgical removal of the tumors along with stereotactic radiosurgery. Pittsburgh, PA (PRWEB) September 18, 2014 Research conducted by a team of neurosurgeons and radiation oncologists from Allegheny Health Network...

2014-09-18 12:30:21

ASHEVILLE, N.C., Sept. 18, 2014 /PRNewswire-USNewswire/ -- The Pediatric Brain Tumor Foundation's Starry Night 8.5K is an evening walk/run to help kids battling one of the deadliest forms of childhood cancer. Starry Night Chicago is coming to Arlington International Racecourse on Saturday, Oct. 4. More than 28,000 children in the United States are living with a brain tumor. Each of the 28,000 steps in Starry Night's 8.5K walk/run will shine light on their illness and raise funds...

2014-09-17 08:28:28

ICT-107 Phase II Update Selected for Oral Presentation at Society for Neuro-Oncology Meeting in November; ICT-121 and ICT-140 Programs on Track LOS ANGELES, Sept. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) provides a corporate update on its plans to advance ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM), and on its portfolio of dendritic cell-based vaccines: ICT-121 for patients...

2014-09-16 08:32:04

HOUSTON, Sept. 16, 2014 /PRNewswire/ -- DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company's lead product, DNX-2401, a replication competent adenovirus plus gamma interferon in a randomized, multicenter, open-label Phase Ib study for patients with recurrent glioblastoma. "DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists in the US, is pleased to announce the initiation of our randomized...

2014-09-16 08:30:30

"PIM" Designation For DCVax-L Is First Step In 2-Step Process for Early Access Approval BETHESDA, Md., Sept. 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that its DCVax-L is the first product to receive formal designation as a "Promising Innovative Medicine" (PIM) under the new "Early Access to Medicines Scheme" (EAMS) launched in the UK...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related